Editor’s note: This is not an exhaustive list. Deals are listed in chronological order from most to least recent.
- McKesson signed a deal with the U.S. to be a central distributor of a COVID-19 vaccine and the supplies needed to administer it.
- Moderna signed a deal with the U.S. valued at up to $1.5 billion for 100 million doses of its COVID-19 vaccine candidate.
- Johnson & Johnson signed a more than $1 billion deal with the U.S. for 100 million doses of its investigational COVID-19 vaccine.
- The U.S. signed a deal with Sanofi and GlaxoSmithKline to pay the drugmakers up to $2.1 billion for the development and supply of a COVID-19 vaccine they are partnering on.
- Pfizer and BioNTech signed a $1.9 billion deal with the U.S. to secure up to 600 million doses of BNT162, the two drugmakers’ jointly-developed COVID-19 vaccine candidate.
- Novavax signed a $1.6 billion deal with the U.S. to expedite development of its COVID-19 vaccine.
- Emergent BioSolutions signed a $628 million deal with the U.S. to ramp up its contract development and manufacturing capabilities to expedite the delivery of COVID-19 vaccines.
- AstraZeneca signed a more than $1 billion deal with the U.S. to support increased access to its COVID-19 vaccine.
More articles on pharmacy:
FDA extends remdesivir’s emergency use authorization to all hospitalized COVID-19 patients
Walgreens names former Rite Aid CEO as its new president
Heads roll at FDA after commissioner’s comments on convalescent plasma
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
